HIV rebound in HIV controllers is associated with a specific fecal microbiome profile
European Journal of Immunology · 2024
DOI: 10.1002/eji.202350809 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Immunology, 2024. Verfasst von Yanhui Cai und 13 weiteren Autor:innen. Beteiligte Einrichtung: Gilead Sciences, Inc., Foster City, California, USA. Hauptthemen laut MEDLINE: HIV Infections, Feces, Gastrointestinal Microbiome, Dysbiosis. Die Arbeit nennt 40 Literaturangaben. Gefördert von: Gilead Sciences.
Abstract (Originalsprache)
HIV infection is associated with gut dysbiosis, and microbiome variability may affect HIV control when antiretroviral therapy (ART) is stopped. The TLR7 agonist, vesatolimod, was previously associated with a modest delay in viral rebound following analytical treatment interruption in HIV controllers (HCs). Using a retrospective analysis of fecal samples from HCs treated with vesatolimod or placebo (NCT03060447), people with chronic HIV (CH; NCT02858401) or without HIV (PWOH), we examined fecal microbiome profile in HCs before/after treatment, and in CH and PWOH. Microbiome diversity and abundance were compared between groups to investigate the association between specific phyla/species, immune biomarkers, and viral outcomes during treatment interruption. Although there were no significant differences in gut microbiome diversity between people with and without HIV, HCs, and CH shared common features that distinguished them from PWOH. there was a trend toward greater microbiome diversity among HCs. Treatment with vesatolimod reduced dysbiosis in HCs. Firmicutes positively correlated with T‐cell activation, while Bacteroidetes and Euryarchaeota inversely correlated with TLR7‐mediated immune activation. Specific types of fecal microbiome abundance (e.g. Alistipes putredinis ) positively correlated with HIV rebound. In conclusion, variability in the composition of the fecal microbiome is associated with markers of immune activation following vesatolimod treatment and ART interruption.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gilead Sciences, Inc., Foster City, California, USA.
- Department of Medicine, University of California San Francisco, San Francisco, California, USA.
- Central Texas Clinical Research, Austin, Texas, USA.
- Midway Immunology and Research Center, Fort Pierce, Florida, USA.
- Orlando Immunology Centre, Orlando, Florida, USA.
- Men's Health Foundation, West Hollywood, California, USA.
ORCID-Profile: Yanhui Cai, Liao Zhang, Christiaan R de Vries, Elena Vendrame, Jeffrey J Wallin
Förderung
- Gilead Sciences
Zitieren
APA
Cai, Y., Podlaha, O., Deeks, S. G., Brinson, C., Ramgopal, M. N., DeJesus, E., Mills, A., Shalit, P., Abdel-Mohsen, M., Zhang, L., de Vries, C. R., Vendrame, E., SenGupta, D., & Wallin, J. J. (2024). HIV rebound in HIV controllers is associated with a specific fecal microbiome profile. European Journal of Immunology. https://doi.org/10.1002/eji.202350809
Vancouver
Cai Y, Podlaha O, Deeks SG, Brinson C, Ramgopal MN, DeJesus E, et al. HIV rebound in HIV controllers is associated with a specific fecal microbiome profile. European Journal of Immunology. 2024. doi:10.1002/eji.202350809
BibTeX
@article{Cai2024,
author = {Cai, Yanhui and Podlaha, Ondrej and Deeks, Steven G and Brinson, Cynthia and Ramgopal, Moti N and DeJesus, Edwin and Mills, Anthony and Shalit, Peter and Abdel-Mohsen, Mohamed and Zhang, Liao and de Vries, Christiaan R and Vendrame, Elena and SenGupta, Devi and Wallin, Jeffrey J},
title = {HIV rebound in HIV controllers is associated with a specific fecal microbiome profile},
journal = {European Journal of Immunology},
year = {2024},
doi = {10.1002/eji.202350809}
}
EUVIMED